Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round up of R&D news in brief

New ADHD drug edges closer to launch

US company Cephalon says it has received an approvable letter from the US Food and Drug Administration for a new drug to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. The drug, which would be sold in the US under the brand name Sparlon, would be co-marketed with a unit of Johnson & Johnson. Dr Chris Kratochvil, an associate psychiatry professor at the University of Nebraska Medical Centre said that although other ADHD drugs such as Novartis' Ritalin and Shire's Adderall were effective overall, doctors needed additional options because not all drugs were effective in individual patients.

30th September 2008

Share

Subscribe to our email news alerts

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...